Radiosynthesis and biodistribution of a histamine H-3 receptor antagonist 4-[3-(4-piperidin-1-yl-but-1-ynyl)-[C-11]benzyl]-morpholine: evaluation of a potential PET ligand




Airaksinen AJ, Jablonowski JA, van der Mey M, Barbier AJ, Klok RP, Verbeek J, Schuit R, Herscheid JDM, Leysen JE, Carruthers NI, Lammertsma AA, Windhorst AD

PublisherELSEVIER SCIENCE INC

2006

Nuclear Medicine and Biology

NUCLEAR MEDICINE AND BIOLOGY

NUCL MED BIOL

33

6

801

810

10

0969-8051

DOIhttps://doi.org/10.1016/j.nucmedbio.2006.05.008



The potent histamine H-3 receptor antagonist JNJ-10181457 (1) was successfully labeled with C in a novel one-pot reaction sequence, with high chemical yield (decay-corrected yield, 28 +/- 8%) and high specific radioactivity (56 +/- 26 GBq/mu mol). The binding of [C-11]1 to H-3 receptors was studied in vitro in rat brain and in vivo in rats and mice. The in vitro binding of [C-11]1 in rat coronal brain slices showed high binding in the striatum, and this binding was blocked by histamine and by two known H-3 antagonists, JNJ-5207852 (2) and unlabeled Compound (1), in a concentration-dependent manner. The biodistribution of [C-11]1 in rats was measured at 5, 10, 30 and 60 min. The uptake of [C-11]1 in regions rich in H-3 receptors was highest at 30 min, giving 0.98%, 1.41%, 1.28% and 1.72% dose/g for the olfactory bulb, hippocampus, striaturn and cerebral cortex, respectively. However, the binding of [C-11]1 in the rat brain could not be blocked by pretreatment with either Compound (2) (30 min or 24 h pretreatment) or cold Compound (1) (30-min pretreatment). The biodistribution of [C-11]1 in a second species (Balb/c mice) showed a higher overall uptake of the radioligand with an average brain uptake of 8.9% dose/g. In C57BL/6H(3)(-/-) knockout mice, a higher brain uptake was also observed. Analyses of metabolites and plasma protein binding were also undertaken. It appeared that [C-11]1 could not specifically label H-3 receptors in rodent brain in vivo. Possible causes are discussed. (c) 2006 Elsevier Inc. All rights reserved.



Last updated on 2024-26-11 at 22:24